Konakion MM

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Phytomenadione

Available from:

Roche Products Pty Ltd

Class:

Medicine Registered

Patient Information leaflet

KONAKION
®
 MM

_PRONOUNCED KOE-NAK-EE-ON_
_contains the active ingredient phytomenadione (also called Vitamin
K1)_
CONSUMER MEDICINE INFORMATION

WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about KONAKION MM.
It does not contain all the available
information.
It does not take the place of talking to
your doctor or pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you receiving
KONAKION MM against the
benefits they expect it will have for
you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT KONAKION MM
IS USED FOR
KONAKION MM contains the active
ingredient phytomenadione.
KONAKION MM is used to treat
excessive bleeding problems.
KONAKION MM belongs to a group
of medicines called Vitamin K.
Vitamin K substances are used to
treat excessive bleeding problems
and work by reversing some of the
causes of excessive bleeding. This
risk of bleeding is usually caused by
the use of too much medication to
prevent blood clots (also known as
anticoagulant medication).
There are many different types of
medicines used to treat bleeding
disorders. KONAKION MM belongs
to one of these groups.
Your doctor, however, may have
prescribed KONAKION MM for
another purpose.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY KONAKION
MM HAS BEEN PRESCRIBED FOR YOU.
BEFORE YOU RECEIVE
KONAKION MM
_WHEN YOU MUST NOT HAVE IT_
DO NOT HAVE KONAKION MM IF:
1. YOU HAVE HAD AN ALLERGIC
REACTION TO KONAKION MM,
ANY OTHER TYPE OF VITAMIN K OR
ANY INGREDIENTS LISTED AT THE END
OF THIS LEAFLET.
 Some symptoms of an allergic
reaction may include:
•
Shortness of breath
•
Wheezing or difficulty
breathing
•
Swelling of the face, lips,
tongue, or other parts of the
body
•
Rash, itching or hives on the
skinIf you use this medicine
after the expiry date has
passed it may not work as
well
2. YOU ARE PREGNANT OR PLAN TO
BECOME PREGNANT.
3. THE AMPOULE IS DAMAGED OR

Summary of Product characteristics

r

Konakion
®
  PI 100604 

1 of 6 
ISPI 2.0 
NAME OF THE MEDICINE 

KONAKION
®

Phytomenadione (Vitamin K
1
) 

_CAS-84-80-0 _

CH
 CH     CH 
=
   C                CH   CH   CH    CH 
             CH
2                                     
        2        2       2            
                   3
3
CH
3
CH
3
O
O
3

DESCRIPTION 

KONAKION contains as the active ingredient phytomenadione (Vitamin K
1
) which is 2-methyl-3-phytyl-
1,4-naphthaquinone.  Phytomenadione is a clear,
yellow, very viscous, odourless or nearly odourless oil with 
a molecular weight of 450.7.  It is insoluble in water, soluble 1 in
70 in alcohol, more soluble in dehydrated 
alcohol; soluble in benzene, chloroform, ether and vegetable oils.
 It is stable in air but decomposes on 
exposure to light. 

KONAKION is available in ampoules. The ampoule contains the active
ingredient phytomenadione 
10mg/mL in a mixed micelles (MM) solution (the micelles are composed
of glycocholic acid and lecithin in 
an aqueous solution).  The MM ampoule also
contains sodium hydroxide, hydrochloric acid and water for 
injection. 

PHARMACOLOGY 

PHARMACODYNAMICS 

As a component of an enzyme system, Vitamin K
1
 promotes the formation in the liver of coagulation factors 
II (prothrombin), VII, IX and X and of the coagulation inhibitors
protein C and protein S, within the body.  
Anticoagulants of the coumarin and indandione series cause a
reversible displacement of Vitamin K
1
 from 
this enzyme system, thereby inhibiting the synthesis of these
factors.  Since this is a competitive 
displacement, KONAKION is a specific antagonist for warfarin and
similar anticoagulants.  It is not capable, 
however, of terminating the action of heparin; for this purpose a salt
of protamine should be used. 

Vitamin K
1
 administration, which promotes synthesis of the abovementione